# Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-analysis of Randomized Controlled Trials

## Authors

- Shao-Huan Lan ([ORCID](https://orcid.org/0000-0002-8663-3161)) — Pharmaceutical Sciences and Medical Technology, Putian University, Putian, China
- Chien-Ming Chao ([ORCID](https://orcid.org/0000-0003-0235-9060)) — Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan
- Shen-Peng Chang ([ORCID](https://orcid.org/0000-0002-9361-4348)) — Yijia Pharmacy, Tainan, Taiwan
- Li-Chin Lu ([ORCID](https://orcid.org/0000-0002-4289-0780)) — School of Management, Putian University, Putian, China
- Tzu-Liang Hsu ([ORCID](https://orcid.org/0000-0003-4235-3923)) — Orthopedic Surgery, Tung’s Taichung MetroHarbor Hospital, Wuqi District, Taichung City, Taiwan

## Article information

- **Journal:** The Ulutas Medical Journal (Ulutas Med J), ISSN 2149-388X
- **Issue:** Volume 8, Issue 3 (2022), pages 100–109
- **Article type:** Meta-Analysis
- **Published online:** 2022-09-09
- **DOI:** [10.5455/umj.20220613080211](https://doi.org/10.5455/umj.20220613080211)
- **Licence:** [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)
- **Article page:** https://www.ulutasmedicaljournal.com/?mno=55300
- **PDF:** https://www.ulutasmedicaljournal.com/pdf/55300.pdf

## Abstract

This meta-analysis assessed the efficacy and safety of iclaprim compared with those of vancomycin in the treatment of acute bacterial skin and skin structure infection (ABSSSI). Only randomized controlled trials (RCTs) comparing the effect of iclaprim with vancomycin on adult patients with ABSSSIs were included. A total of 3 RCTs involving 1260 adult patients with ABSSSIs were enrolled. Iclaprim had a non-inferior clinical response rate compared with vancomycin. Similar trend was observed in the following subgroups: major cutaneous abscesses, cellulitis/erysipelas, wound infections, MRSA, MSSA, Streptococcus pyogenes infections. Finally, no differences were observed between iclaprim and vancomycin regarding the risks of any AE, drug-related AE, severe AE, discontinuation of study drug due to AE, and mortality. In conclusion, iclaprim exhibits non-inferior efficacy compared with vancomycin in the treatment of ABSSSI. Additionally, iclaprim was generally as well tolerated as vancomycin.

## Keywords

Iclaprim; vancomycin; acute bacterial skin and skin structure infection

## How to cite

Lan SH, Chao CM, Chang SP, Lu LC, Hsu TL. Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ulutas Med J. 2022;8(3):100-109. doi:10.5455/umj.20220613080211

## References

1. Soriano A, Stefani S, Pletz MW, Menichetti F. Antimicrobial stewardship in patients with acute bacterial skin and skin structures infections: an international Delphi consensus. J Glob Antimicrob Resist. 2020;22:296-301. https://doi.org/10.1016/j.jgar.2020.02.002
2. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44(6):e397-412. https://doi.org/10.1016/j.jemermed.2012.11.050
3. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377-85. https://doi.org/10.1111/1469-0691.12235
4. Falcone M, Concia E, Giusti M, Mazzone A, Santini C, Stefani S, et al. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Intern Emerg Med. 2016;11(5):637-48. https://doi.org/10.1007/s11739-016-1450-6
5. Roshdy D, Jaffa R, Pillinger KE, Guffey J, Rozario N, Davidson L, et al. Effect of a multifaceted stewardship intervention on antibiotic prescribing and outcomes for acute bacterial skin and skin structure infections. Ther Adv Infect Dis. 2018;5(6):103-9. https://doi.org/10.1177/2049936118786424
6. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51(8):895-903. https://doi.org/10.1086/656431
7. Bassetti M, Carnelutti A, Righi E. The role of methicillin-resistant Staphylococcus aureus in skin and soft tissue infections. Curr Opin Infect Dis. 2017;30(2):150-7. https://doi.org/10.1097/qco.0000000000000353
8. Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D, Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20 Suppl 4:3-18. https://doi.org/10.1111/1469-0691.12463
9. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. https://doi.org/10.1093/cid/ciu296
10. Tirupathi R, Areti S, Salim SA, Palabindala V, Jonnalagadda N. Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium. J Community Hosp Intern Med Perspect. 2019;9(4):310-3. https://doi.org/10.1080/20009666.2019.1651482
11. Lan SH, Lin WT, Chang SP, Lu LC, Chao CM, Lai CC, et al. Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2019;8(3). https://doi.org/10.3390/antibiotics8030137
12. Lan SH, Chang SP, Lai CC, Lu LC, Chao CM. The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(51):e18426. https://doi.org/10.1097/md.0000000000018426
13. Lan SH, Lai CC, Lu LC, Chang SP, Huang HT. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:1415-23. https://doi.org/10.2147/idr.s202160
14. Lan SH, Chang SP, Lai CC, Lu LC, Chao CM. Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2019;8(6). https://doi.org/10.3390/jcm8060776
15. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol. 2006;71(7):941-8. https://doi.org/10.1016/j.bcp.2005.10.052
16. Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs. 2008;9(2):210-25.
17. Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob Agents Chemother. 2009;53(5):2171-5. https://doi.org/10.1128/aac.00129-09
18. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett. 2003;13(23):4217-21. https://doi.org/10.1016/j.bmcl.2003.07.023
19. Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009;53(7):2834-40. https://doi.org/10.1128/aac.01383-08
20. Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM, Jr., et al. A phase 3, randomized, double-blind, multicenter study To evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens (REVIVE-2 Study). Antimicrob Agents Chemother. 2018;62(5):e02580-17. https://doi.org/10.1128/aac.02580-17
21. Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F, File TM, et al. A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens: REVIVE-1. Clin Infect Dis. 2018;66(8):1222-9. https://doi.org/10.1093/cid/cix987
22. Huang DB, File TM, Jr., Torres A, Shorr AF, Wilcox MH, Hadvary P, et al. A phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin for the treatment of Iclaprim Versus Vancomycin Shao-Huan Lan et al. nosocomial pneumonia suspected or confirmed to be due to Gram-positive pathogens. Clin Ther. 2017;39(8):1706-18. https://doi.org/10.1016/j.clinthera.2017.07.007
23. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
24. Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, et al. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2018;52(2):233-40. https://doi.org/10.1016/j.ijantimicag.2018.05.012
25. Noviello S, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, et al. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. J Med Microbiol. 2020;69(4):625-630. https://doi.org/10.1099/jmm.0.001177
26. Huang DB, Noviello S, Balser B, Scaramucci A, Corey GR. A pooled analysis of the safety and efficacy of iclaprim versus vancomycin for the treatment of acute bacterial skin and skin structure infections in patients with intravenous drug use: Phase 3 REVIVE Studies. Clin Ther. 2019;41(6):1090-6. https://doi.org/10.1016/j.clinthera.2019.04.004